Clene Inc. develops and commercializes novel clean-surfaced nanotechnology (CSN) therapeutics, including CNM-Au8, which is currently in Phase 2/3 clinical trials for ALS patients. The company's other products include CNM-AgZn17 for infectious diseases and wound healing, CNM-ZnAg for COVID-19 and immune support, and CNM-PtAu7 for oncology applications. In addition, Clene distributes dietary supplements such as rMetx and KHC46.